tiprankstipranks
Trending News
More News >

Elanco Animal Health Amends Receivables Loan Agreement

Story Highlights
Elanco Animal Health Amends Receivables Loan Agreement

Don’t Miss TipRanks’ Half-Year Sale

Elanco Animal Health ( (ELAN) ) just unveiled an announcement.

On June 25, 2025, Elanco Animal Health Incorporated, along with Elanco SPEAR LLC and Elanco US Inc., amended its Receivables Loan Agreement with Rabobank, extending the term of the agreement to June 26, 2028. This amendment impacts the company’s accounts receivable securitization facility, potentially affecting its financial obligations and operational flexibility.

The most recent analyst rating on (ELAN) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Elanco Animal Health stock, see the ELAN Stock Forecast page.

Spark’s Take on ELAN Stock

According to Spark, TipRanks’ AI Analyst, ELAN is a Outperform.

Elanco Animal Health’s overall stock score is driven by strong financial performance and bullish technical indicators. The company’s solid earnings call results and strategic corporate changes further enhance its growth prospects. However, valuation concerns and external challenges like tariffs temper the score.

To see Spark’s full report on ELAN stock, click here.

More about Elanco Animal Health

Elanco Animal Health Incorporated operates in the animal health industry, focusing on the development and supply of products and services for animal health and well-being.

Average Trading Volume: 6,235,584

Technical Sentiment Signal: Buy

Current Market Cap: $6.83B

For an in-depth examination of ELAN stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1